TSX VENTURE EXCHANGE: AVI
QUEBEC CITY, Dec. 18 /CNW Telbec/ - Advitech Inc. ("Advitech" or the
"Company") (TSX Venture Exchange: AVI) announces the conclusion of a
definitive agreement for the distribution of Dermylex(TM) on the Mexican
market with Laboratorios Dermatologicos Darier S.A. de C.V. ("Darier"), a
pharmaceutical leader in dermatology, specialized in the development and
commercialization of prescription and cosmeceutical products.
"This is a breakthrough agreement for Advitech with Darier, a leading
Mexican pharmaceutical company specializing in dermatology, as it constitutes
our second commercial partnership with a pharmaceutical company specializing
in dermatology," commented Mr. Renaud Beauchesne, President and Chief
executive officer of Advitech.
"This is a significant partnership for Advitech as it further validates
our clinical data and program on Dermylex(TM). It also reinforces our business
strategy, which is to focus mainly on dermatology-oriented distributors, and
it acknowledges the effectiveness of our patented XP-828L technological
platform", added Mr. Beauchesne.
Mr. Fernando Ahumada, President and Chief executive officer of Darier
added: "Laboratorios Dermatologicos Darier is the Mexican leader in
dermatology and with the help of Dermylex(TM); we intend to increase our
market share in psoriasis and collaborate with Advitech to investigate
additional opportunities in dermatology in the Mexican market."
About Darier: www.darier.com.mx:
Darier is a vertically integrated specialty pharmaceutical company that
researches, develops, manufactures and commercializes dermatology products for
Mexico & Latin America. Darier is the market leader in dermatology with more
than 13% in market share in Mexico. Darier's offering includes a broad range
of dermatological products for acne, atopic dermatitis, psoriasis, sunscreens,
and skin cancer. Its strength lies on high product quality, product innovation
and its privileged relationship with dermatologists and pediatricians
cultivated over its 25-year history. Corporate headquarters are located in
Mexico City, and research, development and manufacturing facilities are in
Cuernavaca, Morelos, Mexico.
About Advitech Inc. www.advitech.com:
Advitech is a health sciences and technology company with a mission to
discover and commercialize proprietary and evidence-based natural health
products. Effective and safe, these products play a role in the prevention of
immune-mediated inflammatory disorders, such as psoriasis and inflammatory
bowel disease. Advitech produces Dermylex(TM) for the treatment of
Advitech has drawn up a research program to develop new applications
related to wound healing. This development is derived from both its XP-828L
technological platform and a new colostrums platform.
About Dermylex(TM) www.dermylex.com:
Dermylex(TM), developed by Advitech, is an oral natural health product
formulated to improve mild-to-moderate psoriasis symptoms. Two clinical
trials, including a 112-day, multi-center, double-blind, placebo-controlled
trial with 84 patients, clinically proved the efficacy and safety of
Dermylex(TM) for that type of psoriasis. Dermylex(TM) is currently available
in Canada and the U.S. (as BioDerm, Dermalyx(TM)), as well as in France and
Belgium (as Psopax(R)).
This press release contains forward-looking statements which reflect the
Company's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could differ
materially from those projected herein. The TSX Venture Exchange does not
accept responsibility for the adequacy or accuracy of this release.
For further information:
For further information: Advitech Inc.: Renaud Beauchesne, MBA,
President and Chief Executive Officer, 418-686-7498, ext. 228,
email@example.com, www.advitech.com; Serge Comeau, Investor's relations, (514)
862-4160, firstname.lastname@example.org; Laboratorios Dermatologicos Darier, S.A. de
C.V.: Juan Carlos Lozano, Vice-President Business Development, +52 (55) 5350